论文部分内容阅读
目的探讨胰岛素泵即胰岛素皮下持续输注(CSII)治疗初诊2型糖尿病患者的临床疗效。方法选取通辽市医院2014年8月—2015年8月收治的初诊2型糖尿病住院患者200例,采用随机数字表法分为观察组和对照组,每组100例。其中观察组行CSII治疗,对照组行多次皮下注射胰岛素(MSII)治疗;均治疗2周。比较两组治疗前后空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HomaIR)和胰岛素β细胞指数(Homa-β)。结果两组治疗后FPG和2hPG均较治疗前下降,以观察组为著(P均<0.05);两组Homa-IR较治疗前下降,Homa-β较治疗前升高,差异有统计学意义(P均<0.05),两组之间的比较,P均>0.05;两组HbA1c值比较,P>0.05。结论 CSII可修复初诊2型糖尿病患者的胰岛β细胞功能,促进血糖水平达标。
Objective To investigate the clinical efficacy of insulin pump (insulin infusion subcutaneous continuous infusion (CSII) in the treatment of newly diagnosed type 2 diabetic patients. Methods Totally 200 inpatients with newly diagnosed type 2 diabetes admitted to Tongliao Hospital from August 2014 to August 2015 were randomly divided into observation group (n = 100) and control group (n = 100). The observation group was treated with CSII, and the control group with multiple subcutaneous injections of insulin (MSII); both were treated for 2 weeks. Fasting blood glucose (FPG), postprandial 2h glucose (HbA1c), insulin resistance index (HomaIR) and insulin-β-cell index (Homa-β) were compared between the two groups before and after treatment. Results The FPG and 2hPG in both groups decreased after treatment compared with those before treatment (all P <0.05). Homa-IR in both groups decreased before treatment and Homa-β increased compared with those before treatment, the difference was statistically significant (P <0.05), P> 0.05 between the two groups; HbA1c values of the two groups were compared, P> 0.05. Conclusion CSII can repair islet β-cell function in newly diagnosed type 2 diabetic patients and promote the attainment of blood glucose level.